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Abstract Numerous reports have indicated that intramuscular 
injection of antigen-coding naked plasmid DNA can trigger 
humoral and cell-mediated protective immunity against infection. 
This follows DNA uptake by muscle fibres, leading to the 
expression and extracellular release of the antigen. Here it is 
shown for the first time that intramuscular immunization of mice 
with pRc/CMV HBS (encoding the S region of hepatitis B 
antigen; HBsAg) entrapped into positively charged (cationic) 
liposomes leads to greatly improved humoral and cell-mediated 
immunity. These cationic liposome-entrapped DNA vaccines 
generate titres of anti-HBsAg IgG! antibody isotype in excess of 
100-fold higher and increased levels of both IFN-yand IL-4 when 
compared with naked DNA or DNA complexed with preformed 
similar (cationic) liposomes. It is likely that immunization with 
liposome-entrapped plasmid DNA involves antigen-presenting 
cells locally or in the regional draining lymph nodes. 
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1. Introduction 
Intramuscular injection of antigen-encoding naked plasmid 
D N A can trigger humoral and cell-mediated protective im-
munity against infection [1-4]. Immunity follows D N A uptake 
by muscle fibres, leading to the expression and extracellular 
release of the antigen [5,6]. Potential disadvantages with 
naked D N A vaccination include uptake of D N A by only a 
minor fraction of muscle cells [5], exposure of D N A to nucle-
ases in the interstitial fluid, the use of relatively large quanti-
ties of D N A (e.g. 50-200 \ig per mouse) [5] and, often, the 
need to inject into regenerating muscle in order to enhance 
immunity [5,7,8]. 
Administration of antigen-encoding plasmid D N A via lip-
osome could, on the other hand, circumvent the need of 
muscle involvement and facilitate [9] instead its uptake by 
antigen presenting cells (APC), for instance those infiltrating 
the site of injection or in the lymphatics, at the same time 
protecting D N A from nuclease attack [10]. Moreover, trans-
fection of A P C with liposome-entrapped D N A could be pro-
moted by the judicial choice of vesicle surface charge and lipid 
composition [1,10]. To that end, we have recently developed a 
method [10] which allows for the quantitative entrapment of 
D N A into neutral, anionic and cationic liposomes all of which 
are capable of transfecting cells in vitro with varying efficiency 
[10]. Here, it is shown for the first time that intramuscular 
immunization of mice with pRc /CMV HBS (encoding the S 
region of hepatitis B surface antigen; ayw subtype) entrapped 
into such liposomes leads to improved humoral and cell-medi-
ated immunity. Cationic liposome-entrapped D N A vaccines, 
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for instance, generate titres of IgGi antibody isotype in excess 
of 100-fold higher and increased levels of both IFN-y and IL-4 
when compared with naked D N A or D N A complexed with 
preformed similar (cationic) liposomes. It is likely that immu-
nization with liposome-entrapped plasmid D N A involves anti-
gen-presenting cells (APC) locally or in the regional draining 
lymph nodes. 
2. Materials and methods 
2.1. Materials 
Plasmid pRc/CMV HBS, cloned by Dr. Robert Whalen using pRc/ 
CMV (InVitrogen) as vector backbone, expresses sequences coding for 
the S (small) protein of hepatitis B virus (HBsAg, subtype ayw). 
Recombinant hepatitis B surface antigen (HBsAg) (S region; subtype 
ayw) was purchased from Genzyme, West Mailing, Kent, UK. The 
sources and grades of egg phosphatidylcholine (PC), dioleoyl phos-
phatidylcholine (DOPE), stearylamine (SA), and phosphatidylserine 
(PS) have been described elsewhere [10]. l,2-Dioleoyloxy-3-(trimethyl-
ammonium)propane (DOTAP) was from Avanti Polar Lipids Inc. 
(Alabaster, AL, USA) and 3ß-(Ar,Ar-dimethylaminoethane)carbamyl 
cholesterol (DC-Choi) was a gift from Dr. C. Kirby. 
2.2. Entrapment of plasmid DNA into liposomes 
pRc/CMV HBS mixed with 35S-labelled tracer, was entrapped in 
liposomes as previously described for a luciferase encoding plasmid 
DNA [10]. Briefly, small unilamellar vesicles (SUV) prepared [10,11] 
from 16 umol PC and 8 umol DOPE in the absence (uncharged) or 
presence of either 4 umol PS (anionic) or 4 umol of SA, DOTAP or 
DC-Choi (cationic liposomes), were mixed with 10-100 ug DNA and 
freeze-dried overnight. Following rehydration under controlled con-
ditions [10,11], the generated dehydrated-rehydrated vesicles (DRV 
liposomes) were washed by centrifugation and suspended in 0.15 M 
sodium phosphate buffer supplemented with 0.9% NaCl, pH 7.4 
(PBS). DNA entrapment values were, as expected high for instance 
[10], 53-58% (neutral and anionic) and 77-83% (cationic liposomes) of 
the amount used (results not shown). In some experiments, preformed 
cationic (DOTAP) DRV were mixed with 10-100 ug DNA, incubated 
for 30 min at 20°C and then washed by centrifugation as above. 
Values of complexed DNA were 83-94% of the amount used (results 
not shown). 
2.3. DNA immunisation 
Male Balb/c mice 4-8 weeks old were bled from the tail vein 1-2 
days before a single or several intramuscular (hind leg) injections of 50 
ul PBS containing 1-10 ug naked, complexed or liposome-entrapped 
(about 0.5 mg PC) pRc/CMV HBS (see legends to Figs. \-$ for de-
tails). Animals were bled again at time intervals after the first injection 
and sera (diluted 20-fold in PBS) kept at —40°C. Sera were tested for 
anti-HBsAg (S region; ayw subtype) IgGi, IgCba and IgG2b by the 
enzyme-linked immunoadsorbent assay (ELISA) (using the same anti-
gen to coat the plates) as applied previously [12] for the same antigen. 
Immune response was expressed as the logio of the reciprocal of serial 
3-fold serum dilution required for OD to reach a reading of about 
0.200 (end point dilution). Sera from untreated mice gave logio values 
of less than 2.0. 
2.4. Cytokine extractions 
Endogenous levels of IFN-y and IL-4 in the spleen were determined 
using the method of Nakane et al [13] as previously modified [14]. 
Individual spleens were weighed, homogenized in ice-cold RPMI con-
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taining 1% 3-[(cholamidopropyl)dimethylammonio]-l-propanesulpho-
nate (CHAPS; Sigma) in a Dounce tissue homogenizer and 10% (w/v) 
homogenates were prepared. Homogenates were left on ice for 1 h and 
insoluble debris were then removed by centrifugation at 2000 Xg for 
20 min. The clear supernatants were stored at —70°C. 
2.5. Cytokine assays 
Standard capture ELISAs were used with monoclonal antibody 
pairs and Maxisorp (NUNC, UK) plates. Primary monoclonal anti-
bodies against IFN-y (R46A2) and IL-4 (11B11) and secondary bio-
tinylated anti-mouse IL-4 (BVD6-24G2) and anti-mouse IFN-y 
(XMG1.2) monoclonal antibodies (Pharmingen, USA) were used 
with streptavidin peroxidase (Dako, Denmark) and o-phenylenedi-
amine (Sigma) as substrate. Recombinant IFN-y and IL-4 standards 
were from Pharmingen. Results (mean ± S.D.) are expressed as ng/ 
spleen from at least 4 mice. 
2.6. Statistical analysis 
Significance levels were determined by the Student's i-test for un-
paired observations. 
3. Results and discussion 
In a number of separate experiments, Balb/c mice were in-
jected intramuscularly several times with pRc/CMV-HBS as 
naked DNA, entrapped into uncharged or charged liposomes, 
or complexed with similar preformed cationic liposomes. Fig. 
1 and legend show that in mice injected repeatedly during a 37 
day period with two different doses (5 and 10 |xg) of DNA 
entrapped in positively charged liposomes incorporating a cat-
ionic lipid (DOTAP, DC-Choi or SA), titres of antibody 
(IgGi) responses against the encoded antigen (HBsAg) were 
up to at least 100-fold greater at all times tested (26, 34 and 44 
days after the first injection) than titres in mice immunized 
with naked DNA. IgG2a and IgG2b titres for the liposomal 
DNA were also greater, albeit to a lesser extent (about 10-
fold). 
Complexes of cationic vesicles with plasmid DNA are 
highly effective in transfection in vitro [1,15] and, in a recent 
study [10], one such complex of Lipofectin with DNA (pGL2-
control expressing the luciferase reporter gene from a SV40 
promoter) was 10-100-fold more efficient in transfecting cul-
tured COS-7 cells than the same DNA entrapped by the 
present technique in uncharged or charged liposomes. How-
ever, Lipofectin complexed with antigen-encoded plasmid 
DNA did not augment antibody responses to the antigen in 
another study [16] in vivo. We therefore compared entrapped 
(charged and uncharged liposomes) and complexed (with sim-
ilar cationic liposomes) pRc/CMV-HBS in terms of immune 
responses to the encoded antigen using the same protocol of 
immunization as in Fig. 1. Results (Fig. 2) show that, con-
trary to the aforementioned [10] in vitro transfection efficiency 
data, DNA entrapped in cationic (DOTAP) liposomes pro-
duced greater (over 80-fold) IgGi titres than complexed 
DNA (10 (ig dose; 28 days). Interestingly, uncharged lipo-
somes were also found capable of transfecting entrapped 
DNA although, judging from the antibody titres (Fig. 2, 10 
Hg), with reduced efficiency. Animals from the experiment in 
Fig. 2 were also tested for T cell responses and to that end, 
levels of IFN-y and IL-4 in their spleens, 3 weeks after the 
final immunization, were measured as indicators of Thl and 
Th2 subset T cell activation. The data (Fig. 3) show that 
activation for both Thl and Th2 subsets was greater with 
liposome-entrapped DNA when compared with naked or 
complexed DNA. It therefore appears that immunization 
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Fig. 1. Comparison of immune responses in mice injected with plas-
mid DNA as such or entrapped in different cationic liposomes. 
Balb/c mice in groups of four were injected intramuscularly on days 
0, 10, 20, 27 and 37 with 5 |xg of pRc/CMV HBS entrapped in posi-
tively charged liposomes composed of PC, DOPE and DOTAP (A), 
DC-Choi (B) or SA(C), or in the naked form (D). Animals were 
bled 7, 15, 26, 34 and 44 days after the first injection and sera 
tested for IgGi (white bars), IgG2a (black bars) or IgG2b (dotted 
bars) responses against the encoded antigen hepatitis B surface anti-
gen (HBsAg; S region, ayw subtype). Values are means ± S.D. of 
logio of reciprocal end point serum dilutions required for OD to 
reach readings of about 0.200. Similar values (all groups) were ob-
tained in mice injected as above with 10 (ig DNA in a separate ex-
periment (results not shown). Immune responses were mounted by 
all mice injected with liposomal DNA but became measurable only 
at 26 days. Differences in logio values (all IgG subclasses at all time 
intervals) in mice immunized with liposomal DNA and mice immu-
nized with naked DNA were statistically significant (P< 0.0001-
0.002). 
with liposome-entrapped plasmid DNA induces both humoral 
and cell-mediated immunity. 
Most reports [1,3,4,6,17-20] on naked DNA vaccination 
have employed protocols of multiple injections, but a single 
dose also produces a humoural response to the encoded anti-
gen [5,21]. For instance, total IgG response for the naked 
pRc/CMV HBS (identical to the plasmid used here) was de-
tectable 1-2 weeks after injection, to reach peak values by 4-8 
weeks [5,22]. Under the present conditions of single immuni-
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vesicle uptake by muscle cells after local injection. Instead, 
liposomes enter the lymphatic system to localize in the lymph 
nodes [9] and, indeed, such fate has been implicated in the 
action of liposomes as immunological adjuvants [25]. 
Although positively charged (DNA-containing) liposomes 
could conceivably bind to the negatively charged surface of 
muscle cells and be interiorized by them, this is probably 
prevented by proteins in the interstitial fluid which, on injec-
tion, are expected [23] to confer a net negative charge on the 
liposomal surface. It is more likely that positively charged 
liposomes (in which about 25% of total DNA content is ex-
posed on the vesicle surface [10]) are phagocytosed by APC 
infiltrating the site of injection or in the lymphatics. Phagocy-
tosis can apparently [26] be facilitated by the condensed state 
of the DNA (attained [27] on interaction with cationic lipids) 
and could explain the reduced levels of immune responses 
with DNA entrapped in uncharged or negatively charged lip-
osomes. The fusogenic [27] DOPE component of liposomes, 
possibly in conjunction [27] with the cationic lipid, may then 
mediate DNA entry into the cytoplasm for eventual episomal 
transfection and presentation of the encoded antigen. Regard-
less of the mechanisms involved however, liposome-mediated 
DNA vaccination under the conditions described, appears 
21 28 
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Fig. 2. Comparison of immune responses in mice injected with com-
plexed or liposome-entrapped plasmid DNA. Balb/c mice in groups 
of four were injected intramuscularly on days 0. 7, 14, 21 and 28 
with 1 (white bars) or 10 ug (black bars) of pRc/CMV HBS en-
trapped in positively charged liposomes composed of PC, DOPE 
and DOTAP (A), uncharged liposomes composed of PC and DOPE 
(B), complexed with similar preformed cationic DOTAP liposomes 
(C) or in naked form (D). Sera from animals bled at 7, 14, 21 and 
28 days after the first injection were analysed for anti-HBsAg I g d 
by ELISA. Immune responses were mounted by all mice injected 
with liposomal DNA but became measurable only at 21-28 days. 
For other details see legend to Fig. 1. Differences in logio values 
(10 |ig dose, 21 and 28 days) between mice immunized with cationic 
liposomal DNA and mice immunized with neutral liposomal, com-
plexed and naked DNA as well as differences between neutral or 
liposomal or complexed and naked DNA were statistically signifi-
cant (P< 0.0001-0.005). 
zation (Fig. 4) with much lower doses of pRc/CMV HBS (2 
and 10 |a,g), anti-HBsAg IgGi response for naked and com-
plexed DNA was barely detectable even by 10 weeks. In con-
trast, there was an early and pronounced IgGi response for 
DNA entrapped in cationic liposomes (peaking at 5-7 weeks), 
and a delayed but significant response for DNA entrapped in 
neutral or negatively charged liposomes (Fig. 4 and legend). 
The mechanism of liposome-mediated immunity to the anti-
gen encoded by the plasmid DNA is unknown at present. 
With naked DNA vaccination, several, possibly concurrent, 
pathways leading to Thl and Th2 immunity have been sug-
gested [5,6]. They include secretion of the antigen by the 
DNA-transfected muscle cells and subsequent processing 
and presentation by resident Langerhans cells or infiltrating 
APC; destruction of transfected muscle cells via a Tc cell 
response resulting in release of the antigen; and transfection 
of both muscle cells and resident APC causing simultaneous 
activation of both T cell subsets. Work [23,24] on the fate of 
liposomes in vivo has produced no evidence of significant 
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Fig. 3. Cytokine levels in the spleens of mice immunized with 
naked, complexed or liposome-entrapped plasmid DNA. Mice were 
immunized as in Fig. 2 with pRc/CMV HBS entrapped into either 
positively charged (a) or uncharged liposomes (b), complexed with 
positively charged liposomes (c), or in naked form (d). 'Control' 
represents cytokine levels in normal unimmunized mice. 3 weeks 
after the final injection, mice were killed and their spleens subjected 
to cytokine analysis. Each bar represents the mean ± S.D. of a 
group of 4 mice. Cytokine values in mice immunized with cationic 
liposomes were significantly higher than those in the other groups 
(P< 0.001-0.05). 
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Fig. 4. Immune responses in mice after a single injection of plasmid 
DNA. Balb/c mice in groups of four were injected once intramuscu-
larly with 2 (white bars) or 10 ug (black bars) of pRc/CMV HBS 
entrapped in positively charged liposomes composed of PC, DOPE 
and DOTAP (A), uncharged liposomes composed of PC and DOPE 
(B), complexed with preformed similar DOTAP liposomes (C) or in 
the naked form (D). Anti-HBsAg IgGi responses were analysed 
(ELISA) in sera obtained at time intervals after injection. Immune 
responses were mounted by all mice injected with liposomal DNA 
but became measurable only at 20-27 days. For other details see 
legend to Fig. 1. Differences in logio values (both doses; all time in-
tervals) between mice immunized with cationic liposomal DNA and 
mice immunized with naked DNA were statistically significant 
(P< 0.0001-0.002). In a fifth group of four mice immunized once as 
above with 10 ug pRc/CMV HBS entrapped in anionic liposomes 
composed of PC, DOPE and PS (see Section 2), IgGi immune re-
sponses (logio) were 2.25 ±0.0 and 2.73 ±0.0 at 21 and 29 days, re-
spectively. 
more effective than naked D N A in inducing both humoral 
and cell mediated immunity. 
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